CSPG4 and obstructive sleep apnea syndrome: The demonstration of safety, immunogenicity, and clinical benefit of HuDo-CSPG4 vaccination in canine OSA patients represents a significant step forward consistent with the principles of comparative oncology, which aims to accelerate translational progress from preclinical studies to human clinical settings [190].